Corpus Intelligence IC Memo — ST MARKS HOSPITAL 2026-04-26 05:26 UTC
IC Memo — ST MARKS HOSPITAL
Investment Committee Memorandum | UT | 263 beds | Grade B | EBITDA uplift $39.7M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

ST MARKS HOSPITAL

CCN 460047 | nan, UT | 263 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

ST MARKS HOSPITAL is a 263-bed suburban community hospital in nan, UT with $539.0M in net patient revenue and a 44.0% operating margin. The hospital serves a payer mix of 18.7% Medicare, 5.9% Medicaid, and 75.4% commercial.

Thesis: Platform Growth. Our ML models identify $39.7M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 44.0% to 51.4% (+736bps).

Net Revenue HCRIS$539.0M
Current EBITDA COMPUTED$237.1M
Operating Margin COMPUTED44.0%
Occupancy HCRIS56.8%
Revenue / Bed COMPUTED$2.0M
Net-to-Gross HCRIS19.3%
Distress Probability ML44.7%

2. Market Context & Competitive Position

59
UT Hospitals
8.0%
State Median Margin
10
Comparable Hospitals

UT has 59 Medicare-certified hospitals with a median operating margin of 8.0%. The target's margin of 44.0% places it above the state median. Among 10 size-comparable peers (132-526 beds), the median margin is 12.0%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (132-526), prioritizing same-state peers. 10 hospitals in the comp set.

HospitalStateBedsRevenueMargin
ST MARKS HOSPITAL (Target)UT263$539.0M44.0%
INTERMOUNTAIN MEDICAL CENTERUT486$1.24B8.9%
PRIMARY CHILDRENS HOSPITALUT287$895.5M5.6%
ST GEORGE REGIONAL HOSPITALUT256$790.1M12.0%
UTAH VALLEY HOSPITALUT338$707.3M7.6%
MCKAY-DEE HOSPITALUT236$629.9M12.6%
LDS HOSPITALUT216$307.0M-5.5%
OGDEN REGIONAL MEDICAL CENTERUT174$299.3M47.4%
JORDAN VALLEY MEDICAL CENTERUT267$274.2M17.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $39.7M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$11.3M+210bp18mo
Cost to Collect4.5%2.5%$10.8M+200bp12mo
Denial Rate Reduction12.0%6.5%$10.7M+198bp12mo
A/R Days Reduction5200.0%3800.0%$6.6M+122bp9mo
Clean Claim Rate88.0%96.0%$345K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$11.3M
Cost to Collect
$10.8M
Denial Rate Reduction
$10.7M
A/R Days Reduction
$6.6M
Clean Claim Rate
$345K
Total EBITDA Uplift$39.7M
Current EBITDA$237.1M
+ RCM Uplift+$39.7M
Pro Forma EBITDA$276.8M
Current Margin44.0%
Pro Forma Margin51.4%
WC Released (1x)$20.7M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$364.8M$1.96B5.38x40.0%
Base (11x exit)10.0x11.0x$364.8M$2.28B6.24x44.2%
Bull Case9.0x11.0x$328.3M$2.52B7.69x50.4%
Bull (12x exit)9.0x12.0x$328.3M$2.85B8.68x54.1%
Bear Case11.0x10.0x$401.3M$1.64B4.10x32.6%
Bear (11x exit)11.0x11.0x$401.3M$1.94B4.83x37.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 10 hospitals with 132-526 beds
  • Same-state prioritization (n=11)
  • Comp margins: P25=7.6% / P50=12.0% / P75=17.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.